Clinical epidemiology and molecular biology of cutaneous and mucosal melanoma in Girona 1994-2018
In this doctoral thesis, the epidemiology of cutaneous and mucosal melanoma is analyzed, as well as its molecular profile to provide new knowledge on a population basis in the province of Girona. The cancer registry of Girona was used as a high reliable a source of cases. The incidence and overall/r...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | CBUC, CESCA |
| Repositorio: | TDR. Tesis Doctorales en Red |
| OAI Identifier: | oai:www.tdx.cat:10803/688699 |
| Acceso en línea: | http://hdl.handle.net/10803/688699 |
| Access Level: | acceso abierto |
| Palabra clave: | Melanoma Epidemiologia descriptiva Epidemiología descriptiva Desrciptive epidemiology Biologia molecular Biología molecular Molecular biology Càncer Cáncer Cancer Incidència Incidencia Incidence Supervivència Supervivencia Survival Girona Genètica Genética Genetics 311 575 577 616 |
| Sumario: | In this doctoral thesis, the epidemiology of cutaneous and mucosal melanoma is analyzed, as well as its molecular profile to provide new knowledge on a population basis in the province of Girona. The cancer registry of Girona was used as a high reliable a source of cases. The incidence and overall/relative survival at 5 and 10 years are described, in addition, a molecular analysis of the BRAF gene in cutaneous melanoma and a genetic panel in mucosal melanoma is performed. In addition, medical evidence is provided for the treatment of patients in daily clinical practice. Overall survival at 5 years for all stages in cutaneous melanomas is 81% similar to other published studies with a prevalence of mutations in the BRAF gene around 50% and stage being the only statistically significant prognostic factor for the survival. It is confirmed that BRAF gene mutation is not a prognostic factor. 5-year overall survival for all stages in mucosal melanomas is around 21%, also similar to other published studies. Vulvo-vaginal melanomas have better survival. The molecular profile where mutations in NRAS and NF1 dominate is different from cutaneous melanoma and we corroborate that they have a clearly worse prognosis |
|---|